ALTERITY THERAPEUTICS

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

10 أبريل 2025 06:35:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

03 أبريل 2025 06:35:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

27 مارس 2025 06:25:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics Raises A$40.0 million in Placement

10 فبراير 2025 06:25:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

30 يناير 2025 06:35:00 بحسب Nasdaq GlobeNewswire

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

24 يناير 2025 06:35:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

09 يناير 2025 06:25:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

04 ديسمبر 2024 06:35:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

19 نوفمبر 2024 06:25:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

12 نوفمبر 2024 06:35:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

06 نوفمبر 2024 06:35:00 بحسب Nasdaq GlobeNewswire

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

31 أكتوبر 2024 06:35:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

14 أكتوبر 2024 06:35:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

11 أكتوبر 2024 06:35:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

02 أكتوبر 2024 06:35:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

30 سبتمبر 2024 06:35:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

23 سبتمبر 2024 06:35:00 بحسب Nasdaq GlobeNewswire

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

31 يوليو 2024 06:35:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics to Present at MST Financial Webinar

24 يوليو 2024 06:35:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

17 يوليو 2024 06:35:00 بحسب Nasdaq GlobeNewswire